HAIRY CELL LEUKEMIA
Clinical trials for HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets rare blood cancer
Disease control OngoingThis early-phase study tests the safety of combining two drugs, Lumoxiti and Rituximab, for people with hairy cell leukemia that hasn't responded to standard treatment. Participants receive up to 8 cycles of the drugs through an IV. The goal is to find a safe dose and see if the …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:10 UTC
-
New drug combo shows promise for rare leukemia
Disease control OngoingThis study tests a combination of two drugs, vemurafenib (a pill) and obinutuzumab (given by IV), in 30 people with untreated hairy cell leukemia. The goal is to see how many patients achieve a complete response (no signs of cancer). Participants take vemurafenib for 4 months and…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:02 UTC
-
New hope for rare leukemia: targeted pill shows promise in relapsed patients
Disease control OngoingThis study tests a drug called ibrutinib in people whose hairy cell leukemia has come back after treatment. Ibrutinib works by blocking a key enzyme that cancer cells need to grow. The goal is to see if the drug can shrink or control the cancer. About 44 adults with this rare blo…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:59 UTC